Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| MRK | COURT-RULING | neutral | 1/10 | This is a routine procedural order granting an attorney's application for pro hac vice admission in a case where Merck & | Sep 10, 2026 |
| ISPC | 8-K | bearish | 8/10 | iSpecimen Inc. (ISPC) received a Nasdaq deficiency letter on September 8, 2026, granting an extension until November 25, | Sep 10, 2026 |
| CSBR | 8-K | bullish | 6/10 | Champions Oncology reported Q1 FY2027 revenue of $15.2M, up 8.8% YoY, with oncology services margin improving to 51% fro | Sep 10, 2026 |
| ONC | CLUSTER | neutral | 3/10 | Director Wang Xiaodong executed a large derivative exercise and sold a substantial block of shares totaling ~$13.4M in o | Sep 10, 2026 |
| SEPN | PRESS-RELEASE | neutral | 2/10 | Septerna granted a 275,000-share non-qualified stock option inducement award to newly appointed CMO Rajiv Patni under th | Sep 10, 2026 |
| TWST | CLUSTER | neutral | 2/10 | Four Twist Bioscience insiders, including CEO Emily Leproust and CAO Robert Werner, sold a total of $473K in open-market | Sep 10, 2026 |
| HELP | 6-K | neutral | 2/10 | Helus Pharma (Cybin Inc.) announced CEO Michael Halstead will participate in a fireside chat at the Morgan Stanley 24th | Sep 10, 2026 |
| AMGN | ANALYST-DOWNGRADE | bearish | 4/10 | HSBC double-downgraded AMGN from Buy to Hold on September 10, 2026, cutting its price target to $425 from $445, a 4.5% r | Sep 10, 2026 |
| RDY | 6-K | neutral | 5/10 | No summary provided | Sep 10, 2026 |
| RDY | 6-K | neutral | 2/10 | Dr. Reddy's filed a routine 6-K reporting the allotment of 375 equity shares upon exercise of stock options under its AD | Sep 10, 2026 |
| APTN | EFFECT | neutral | 3/10 | The SEC declared effective Adaptin Bio's S-1 registration statement (File No. 333-298622) on September 9, 2026, covering | Sep 10, 2026 |
| GSK | 6-K | neutral | 1/10 | This is a routine 6-K filing disclosing a PDMR transaction: Maya Martinez-Davis, President US, acquired 9.837 notional A | Sep 10, 2026 |
| NTHI | 8-K | bearish | 6/10 | NeOnc Technologies is executing a $15M registered direct offering, selling shares, pre-funded warrants, and common warra | Sep 10, 2026 |
| NTHI | 424B5 | bearish | 6/10 | NeOnc Technologies is raising approximately $13.9M in net proceeds through a registered direct offering of 2,610,715 sha | Sep 10, 2026 |
| CADL | 8-K | neutral | 4/10 | Candel Therapeutics appointed Martine Zimmermann, PharmD, to its Board of Directors, effective September 8, 2026, increa | Sep 10, 2026 |
| ONCY | 8-K | neutral | 4/10 | Oncolytics Biotech announced positive preclinical results combining its lead candidate pelareorep with a pan-RAS inhibit | Sep 10, 2026 |
| BCDA | 8-K | neutral | 3/10 | BioCardia filed an 8-K announcing that CEO Peter Altman will present at the H.C. Wainwright 28th Annual Global Investmen | Sep 10, 2026 |
| OPTH | 6-K | bullish | 5/10 | Optimi Health announced a Health Canada-authorized Phase 2 clinical trial evaluating psilocybin-assisted therapy for maj | Sep 10, 2026 |
| IRON | 8-K | bullish | 7/10 | Disc Medicine announced positive initial Phase 2 data for DISC-3405 in polycythemia vera (PV) at the SOHO conference. Th | Sep 10, 2026 |
| TTRX | 8-K | neutral | 3/10 | Turn Therapeutics (TTRX) announced it will present at the Stifel 2026 Virtual Immunology and Inflammation Forum on Septe | Sep 10, 2026 |
| PRLD | 8-K | bullish | 6/10 | Prelude Therapeutics announced FDA clearance of its IND for PRT13722, a first-in-class oral KAT6A selective degrader for | Sep 10, 2026 |
| SCYX | 8-K | neutral | 2/10 | SCYNEXIS announced the retirement of CFO Ivor Macleod effective September 9, 2026, and the immediate appointment of Sanj | Sep 10, 2026 |
| VRCA | PRESS-RELEASE | bullish | 5/10 | Verrica Pharmaceuticals announced positive post-hoc data from Phase 3 trials of YCANTH for molluscum contagiosum, showin | Sep 10, 2026 |
| BLRX | 6-K | mixed | 5/10 | BioLineRx announced that two abstracts for its lead asset GLIX1 (a TET2 activator for glioblastoma) were accepted for pr | Sep 10, 2026 |
| ADAG | 6-K | bullish | 5/10 | Adagene announced that its partner Third Arc Bio selected the first lead candidate under their amended strategic collabo | Sep 10, 2026 |
| KMDA | 6-K | neutral | 2/10 | Kamada announced that CEO Amir London will present at the H.C. Wainwright 28th Annual Global Investment Conference on Se | Sep 10, 2026 |
| GSK | 6-K | neutral | 3/10 | GSK announced that Japan's MHLW approved a prefilled syringe presentation of Shingrix for shingles prevention. The ready | Sep 10, 2026 |
| LPCN | 8-K | neutral | 2/10 | Lipocine Inc. filed an 8-K announcing management will present and meet with investors at the H.C. Wainwright 28th Annual | Sep 10, 2026 |
| IPHA | 6-K | neutral | 3/10 | Innate Pharma filed a 6-K announcing a conference call on September 17, 2026, to discuss first-half 2026 financial resul | Sep 10, 2026 |
| CAMP | PRESS-RELEASE | neutral | 4/10 | CAMP4 received MHRA authorization to include UK sites in its global Phase 1/2 trial of CMP-002 for SYNGAP1-related disor | Sep 10, 2026 |